| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
D Jeffrey Keyser is Director at LTRN. D Jeffrey Keyser's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $57K at current prices.
Net of sales, the LTRN filings show accumulation of 58,544 shares.
D Jeffrey Keyser has 8 Form 4 filings on record from June 2020 to May 2026, all as Director at Lantern Pharma (LTRN), 2020–2026.
The 14 reported transactions were 7 option or other derivative awards, 3 open-market purchases, 2 dispositions back to the company and 1 option exercise, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $250K and no sales.
The largest open-market purchase was 10,000 shares of LTRN at an average $15.00 on June 11, 2020, about $150K.